AACR22: Am­gen re­veals new long-term da­ta for Lumakras, look­ing to keep press­ing mar­ket ad­van­tage over Mi­rati

NEW OR­LEANS — Am­gen at­tempt­ed to fur­ther pull away from Mi­rati Ther­a­peu­tics in the KRAS space, tout­ing a new batch of long-term non-small cell lung can­cer da­ta at AACR for its ap­proved drug Lumakras.

In a pooled dataset of 172 NSCLC pa­tients from its Phase I and Phase II stud­ies, Am­gen re­port­ed an ob­jec­tive re­sponse rate of 40.7% af­ter two years, in­clud­ing five com­plete re­spons­es and 65 par­tial re­spons­es. The big biotech al­so found that 32.5% of these pa­tients sur­vived af­ter two years of treat­ment, and the me­di­an OS was 12.5 months with a me­di­an 24.9 months of fol­low-up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.